Table II.
Clinicopathological features of ccRCC patients and association between RASSF1A and RASSF1C mRNA levels and clinical data.
| RASSF1A qPCR results (%) | RASSF1C qPCR results (%) | ||||||
|---|---|---|---|---|---|---|---|
|
|
|
||||||
| Patients (n=86) | Subgroups | Low (≤0.266) | High (>0.266) | P-value (low vs. high)a | Low (≤0.191) | High (>0.191) | P-value (low vs. high)a |
| Age (years) | ≤62 | 31 (36) | 14 (16) | 0.65 | 14 (16) | 31 (36) | 1.00 |
| 62.16±11.24 | >62 | 26 (30) | 15 (18) | 12 (14) | 29 (34) | ||
| Range, 33–83 | |||||||
| Gender | Female (n=38) | 23 (27) | 15 (17) | 0.36 | 13 (15) | 25 (29) | 0.49 |
| Male (n=48) | 34 (40) | 14 (16) | 13 (15) | 35 (41) | |||
| Tumor size (cm) | ≤7 (n=50) | 33 (38) | 17 (20) | 1.00 | 15 (18) | 35 (41) | 1.00 |
| >7 (n=36) | 24 (28) | 12 (18) | 11 (13) | 24 (28) | |||
| Fuhrman's | |||||||
| histological grade | 1 + 2 (n=37) | 16 (19) | 21 (24) | 0.0002 | 11 (13) | 26 (30) | 1.00 |
| 3 + 4 (n=49) | 41 (42) | 8 (9) | 14 (16) | 35 (41) | |||
| TNM stage | |||||||
| Non-metastatic | T1-2N-0M0 | 24 (28) | 21 (24) | 0.011 | 14 (16) | 31 (36) | 1.00 |
| Metastatic | T1-2N1M0 | ||||||
| T3-N0-1M0 | |||||||
| T4-N0-2M0 | |||||||
| T1-4N2M0 | |||||||
| T1-4N0-2M1 | 33 (39) | 8 (9) | 12 (14) | 29 (34) | |||
a
P-values were calculated by Fisher's 2×2 test.